期刊文献+

ddPCR与ARMS-PCR检测NSCLC患者EGFR基因T790M突变的比较研究

Comparative Analysis of EGFR T790M Detection by ddPCR and ARMS-PCR in NSCLC Patients
原文传递
导出
摘要 目的:通过对比微滴式数字PCR(droplet digital PCR,ddPCR)和突变扩增阻滞系统PCR(amplification refractory mutation system PCR,ARMS-PCR)检测非小细胞肺癌(non-small cell lung cancer,NSCLC)表皮生长因子受体(epidermal growth factor receptor,EGFR)基因T790M突变的检测效能,综合分析两种检测方法的优势及适用范围。方法:回顾性收集115例NSCLC患者的标本,同时使用ddPCR和ARMS-PCR两种方法检测EGFR基因T790M突变状态,比较两种方法的检测结果,并分析不同样本类型对ddPCR检测结果的影响。结果:ddPCR检测T790M阳性率为65.2%,ARMS-PCR阳性率为27.8%,ddPCR检测敏感性显著高于ARMS-PCR(P<0.05),两种方法检测一致率为62.6%。ddPCR+ARMS-样本的T790M平均阳性微滴数和平均突变丰度(11,0.35%)均显著低于ddPCR+ARMS+样本(632.3,17.7%)。ddPCR检测基因组DNA和外周血游离DNA阳性率分别为55.9%和78.7%,不同样本类型T790M突变阳性微滴数和突变丰度无显著差别。结论:ddPCR和ARMS-PCR均可用于NSCLC患者EGFR基因T790M突变检测,二者具有良好的一致性,ddPCR具有更高的灵敏性,在检测突变丰度较低的样本方面具有优势。 Objective:This study aimed to compare the detective efficacy of droplet digital polymerase chain reaction(ddPCR)and amplification refractory mutation system(ARMS)-PCR in detecting epidermal growth factor receptor(EGFR)T790M mutation in non-small cell lung cancer(NSCLC)patients,and evaluate the clinical application value of these two techniques.Methods:115 specimens retrospectively collected from NSCLC patients were simultaneously detected by ddPCR and ARMS-PCR,and the results were comprehensively analyzed.The influence of different sample type on detecting results was also explored.Results:The T790M positive rate by ddPCR and ARMS-PCR were 65.2%and 27.8%,respectively.The sensitivity of ddPCR was significantly higher than that of ARMS-PCR(P<0.05),and the consistency of these two methods was 62.6%.The mean T790M mutant droplet number and mean mutant abundance of ddPCR+ARMS-group(11,0.35%)were significantly lower than those of the ddPCR+ARMS+group(632.3,17.7%).The positive rates of T790M mutation in genomic DNA and peripheral blood cell-free DNA by ddPCR are 55.9%and 78.7%,respectively.There was no significant difference between the mean T790M mutant droplet number and mean mutant abundance in different sample types.Conclusion:ddPCR and ARMS-PCR are both convenient and efficient methods for T790M detection,and they are relatively consistent with each other.However,ddPCR has a higher sensitivity than ARMS-PCR,so that it has an advantage in detecting samples with low mutant abundance.
作者 李月 徐玉霞 Li Yue;Xu Yuxia(State Key Laboratory of Oncology in South China,Sun Yat-sen University Cancer Center,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center,Guangzhou 510060,Guangdong,China)
出处 《肿瘤预防与治疗》 2022年第3期211-216,共6页 Journal of Cancer Control And Treatment
基金 国家自然科学基金(编号:82002561) 广东省基础与应用基础研究基金(编号:2020A1515010098)。
关键词 EGFR基因 T790M突变 ddPCR ARMS-PCR 非小细胞肺癌 EGFR T790M mutation ddPCR ARMS-PCR non-small cell lung cancer
  • 相关文献

参考文献3

二级参考文献30

  • 1Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line sin- gle-agent iressa versus gemcitabine and cisplatin trial in nev- er-smokers with adenocarcinoma of the lung[J].J Clin Oncol, 2012, 30(10) :1122-1128.
  • 2Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR muta- tion-positive non-small-cell lung cancer (OPTIMAL, C'TONG-802): a multicentre, open-label, randomised, phase 3 study []]. Lancet Oncol, 2011, 12(8):735-742.
  • 3Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung ade- nocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain[J]. PLoS Med, 2005, 2(3):e73.
  • 4Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors[J]. Sci Transl Med, 2011, 3(75):26-75.
  • 5Maheswaran S, Sequist LV, Nagrath S, et al. Detection of muta- tions in EGFR in circulating lung-cancer cells[J]. N Engl J Med, 2008, 359 (4) :366-377.
  • 6Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-smaUcell lung cancer[J], j Clin Oncol, 2012, 30 (4) :433-440.
  • 7PaezJG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy[]]. Science, 2004, 304(5676):1497-1500.
  • 8Kimura H, Suminoe M, Kasahara K, et al. Evaluation of epidermal growth factor receptor mutation stares in serum DNA as a predictor of response to gefifinib (IILESSA)[J]. BrJ Cancer, 2007, 97(6):778-784.
  • 9Bell DW, Haber DA. A blood-based test for epidermal growth fac- tor receptor mutations in lung cancer[J]. Clin Cancer Res, 2006, 12 (13):3875-3877.
  • 10Ellison G, Donald E, Mcwalter G, et al. A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy sam- ples[J].J Exp Clin Cancer Res, 2010, 29:132.

共引文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部